MDT Quote, Financials, Valuation and Earnings

Jazz Pharmaceuticals PLC has a net margin of 15.61% compared to Medtronic PLC's net margin of 17.56%. Medtronic PLC's return on equity of 8.56% beat Jazz Pharmaceuticals PLC's return on equity of 14.39%.

Medtronic PLC has a consensus price target of $96.83, signalling upside risk potential of 14.98%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $192.72 which suggests that it could grow by 89.41%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Medtronic PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Medtronic PLC.

Medtronic PLC has a beta of 0.794, which suggesting that the stock is 20.554% less volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.096%.

Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.33%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic PLC quarterly revenues are $8.3B, which are larger than Jazz Pharmaceuticals PLC quarterly revenues of $1.1B. Medtronic PLC's net income of $1.3B is higher than Jazz Pharmaceuticals PLC's net income of $191.1M. Notably, Medtronic PLC's price-to-earnings ratio is 25.60x while Jazz Pharmaceuticals PLC's PE ratio is 11.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.29x versus 1.61x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 15.61% compared to Medtronic PLC's net margin of 15.24%. Medtronic PLC's return on equity of 8.56% beat Johnson & Johnson's return on equity of 19.98%.

Medtronic PLC has a consensus price target of $96.83, signalling upside risk potential of 14.98%. On the other hand Johnson & Johnson has an analysts' consensus of $169.73 which suggests that it could grow by 9.96%. Given that Medtronic PLC has higher upside potential than Johnson & Johnson, analysts believe Medtronic PLC is more attractive than Johnson & Johnson.

Medtronic PLC has a beta of 0.794, which suggesting that the stock is 20.554% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.33%. Johnson & Johnson offers a yield of 3.21% to investors and pays a quarterly dividend of $1.24 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic PLC quarterly revenues are $8.3B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Medtronic PLC's net income of $1.3B is lower than Johnson & Johnson's net income of $3.4B. Notably, Medtronic PLC's price-to-earnings ratio is 25.60x while Johnson & Johnson's PE ratio is 26.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.29x versus 4.22x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 15.61% compared to Medtronic PLC's net margin of 32.59%. Medtronic PLC's return on equity of 8.56% beat Eli Lilly and's return on equity of 80.24%.

Medtronic PLC has a consensus price target of $96.83, signalling upside risk potential of 14.98%. On the other hand Eli Lilly and has an analysts' consensus of $1,008.89 which suggests that it could grow by 33.74%. Given that Eli Lilly and has higher upside potential than Medtronic PLC, analysts believe Eli Lilly and is more attractive than Medtronic PLC.

Medtronic PLC has a beta of 0.794, which suggesting that the stock is 20.554% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.33%. Eli Lilly and offers a yield of 0.72% to investors and pays a quarterly dividend of $1.50 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic PLC quarterly revenues are $8.3B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Medtronic PLC's net income of $1.3B is lower than Eli Lilly and's net income of $4.4B. Notably, Medtronic PLC's price-to-earnings ratio is 25.60x while Eli Lilly and's PE ratio is 64.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.29x versus 15.14x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Perrigo Co PLC has a net margin of 15.61% compared to Medtronic PLC's net margin of -3.91%. Medtronic PLC's return on equity of 8.56% beat Perrigo Co PLC's return on equity of -3.76%.

Medtronic PLC has a consensus price target of $96.83, signalling upside risk potential of 14.98%. On the other hand Perrigo Co PLC has an analysts' consensus of $34.60 which suggests that it could grow by 38.4%. Given that Perrigo Co PLC has higher upside potential than Medtronic PLC, analysts believe Perrigo Co PLC is more attractive than Medtronic PLC.

Medtronic PLC has a beta of 0.794, which suggesting that the stock is 20.554% less volatile than S&P 500. In comparison Perrigo Co PLC has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.326%.

Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.33%. Perrigo Co PLC offers a yield of 4.47% to investors and pays a quarterly dividend of $0.29 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Perrigo Co PLC pays out -88.77% of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic PLC quarterly revenues are $8.3B, which are larger than Perrigo Co PLC quarterly revenues of $1.1B. Medtronic PLC's net income of $1.3B is higher than Perrigo Co PLC's net income of -$44.5M. Notably, Medtronic PLC's price-to-earnings ratio is 25.60x while Perrigo Co PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.29x versus 0.79x for Perrigo Co PLC. Usually stocks with elevated PS ratios are considered overvalued.